|
|
||||||||
Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee 53202, USA.
OBJECTIVES: A human immunodeficiency virus (HIV) intervention trial for women at high risk for acquired immunodeficiency syndrome and attending an urban clinic was reported previously. The behavioral group intervention was shown to increase condom use behaviors significantly. This study retrospectively assessed the intervention's cost-effectiveness. METHODS: Standard methods of cost and cost-utility analysis were used. RESULTS: The intervention cost was just over $2000 for each quality-adjusted life-year saved; this is favorable compared with other life-saving programs. However, the results are sensitive to changes in some model assumptions. CONCLUSIONS: Under most scenarios, the HIV prevention intervention was cost-effective.
This article has been cited by other articles:
![]() |
J. Hornberger, M. Holodniy, K. Robertus, M. Winnike, E. Gibson, and E. Verhulst A Systematic Review of Cost-Utility Analyses in HIV/AIDS: Implications for Public Policy Med Decis Making, December 1, 2007; 27(6): 789 - 821. [Abstract] [PDF] |
||||
![]() |
N. L. VanDevanter, P. Messeri, S. E. Middlestadt, A. Bleakley, C. R. Merzel, M. Hogben, R. Ledsky, C. K. Malotte, R. M. Cohall, T. L. Gift, et al. A Community-Based Intervention Designed to Increase Preventive Health Care Seeking Among Adolescents: The Gonorrhea Community Action Project Am J Public Health, February 1, 2005; 95(2): 331 - 337. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Howell, R. B. Greifinger, and A. S. Sommers What Is Known About the Cost-Effectiveness of Health Services for Returning Prisoners? Journal of Correctional Health Care, April 1, 2004; 10(3): 399 - 436. [Abstract] [PDF] |
||||
![]() |
D. R. Holtgrave HIV Prevention, Cost-Utility Analysis, and Race/Ethnicity: Methodological Considerations and Recommendations Med Decis Making, March 1, 2004; 24(2): 181 - 191. [Abstract] [PDF] |
||||
![]() |
C Bonell and J Imrie Behavioural interventions to prevent HIV infection: rapid evolution, increasing rigour, moderate success Br. Med. Bull., September 1, 2001; 58(1): 155 - 170. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Y. Wang, M. Davis, L. Robin, J. Collins, K. Coyle, and E. Baumler Economic Evaluation of Safer Choices: A School-Based Human Immunodeficiency Virus, Other Sexually Transmitted Diseases, and Pregnancy Prevention Program Arch Pediatr Adolesc Med, October 1, 2000; 154(10): 1017 - 1024. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Pinkerton and D. R. Holtgrave How HIV Treatment Advances Affect the Cost--Effectiveness of Prevention Med Decis Making, January 1, 2000; 20(1): 89 - 94. [Abstract] [PDF] |
||||
![]() |
E. H. Kaplan Implicit Valuation of a Blood-exclusion Decision Med Decis Making, April 1, 1999; 19(2): 207 - 213. [Abstract] [PDF] |
||||
![]() |
S. D. Pinkerton, D. R. Holtgrave, L. C. Leviton, D. A. Wagstaff, and P. R. Abramson Model-Based Evaluation of Hiv Prevention Interventions Eval Rev, April 1, 1998; 22(2): 155 - 174. [Abstract] [PDF] |
||||
![]() |
Behavioral Sessions Found Cost-Effective for HIV Prevention Journal Watch Women's Health, December 1, 1996; 1996(1201): 21 - 21. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |